The role of CTLA-4 in the regulation and initiation of T-cell responses
- PMID: 9010718
- DOI: 10.1111/j.1600-065x.1996.tb00919.x
The role of CTLA-4 in the regulation and initiation of T-cell responses
Similar articles
-
The complexities of T-cell co-stimulation: CD28 and beyond.Immunol Rev. 1996 Oct;153:155-82. doi: 10.1111/j.1600-065x.1996.tb00924.x. Immunol Rev. 1996. PMID: 9010723 Review. No abstract available.
-
CD80 (B7-1) and CD86 (B7-2): potential targets for immunotherapy?Res Immunol. 1995 Mar-Apr;146(3):183-96. doi: 10.1016/0923-2494(96)80256-2. Res Immunol. 1995. PMID: 8525052 Review. No abstract available.
-
New protein steals the show as 'costimulator' of T cells.Science. 1993 Nov 5;262(5135):844-5. doi: 10.1126/science.7694360. Science. 1993. PMID: 7694360 No abstract available.
-
CD28/CTLA-4 receptor structure, binding stoichiometry and aggregation during T-cell activation.Res Immunol. 1995 Mar-Apr;146(3):130-40. doi: 10.1016/0923-2494(96)80246-x. Res Immunol. 1995. PMID: 8525042 Review. No abstract available.
-
Role of the CD28-B7 costimulatory pathways in T cell-dependent B cell responses.Adv Immunol. 1996;62:131-66. doi: 10.1016/s0065-2776(08)60429-0. Adv Immunol. 1996. PMID: 8781268 Review. No abstract available.
Cited by
-
A role of suppressor of cytokine signaling 3 (SOCS3/CIS3/SSI3) in CD28-mediated interleukin 2 production.J Exp Med. 2003 Feb 17;197(4):425-36. doi: 10.1084/jem.20020939. J Exp Med. 2003. PMID: 12591901 Free PMC article.
-
An immune-active tumor microenvironment favors clinical response to ipilimumab.Cancer Immunol Immunother. 2012 Jul;61(7):1019-31. doi: 10.1007/s00262-011-1172-6. Epub 2011 Dec 7. Cancer Immunol Immunother. 2012. PMID: 22146893 Free PMC article. Clinical Trial.
-
Relation of three polymorphisms of the CTLA-4 gene in patients with Graves' disease.J Endocrinol Invest. 2002 Mar;25(3):208-13. doi: 10.1007/BF03343992. J Endocrinol Invest. 2002. PMID: 11936461
-
Long-term remission following antithyroid drug withdrawal in patients with Graves' hyperthyroidism: parameters with prognostic value.Endocrine. 2019 Feb;63(2):316-322. doi: 10.1007/s12020-018-1785-z. Epub 2018 Oct 17. Endocrine. 2019. PMID: 30334140
-
B7-2 expressed on EL4 lymphoma suppresses antitumor immunity by an interleukin 4-dependent mechanism.J Exp Med. 1999 Mar 15;189(6):919-30. doi: 10.1084/jem.189.6.919. J Exp Med. 1999. PMID: 10075975 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources